mTOR complex 2 is an integrator of cancer metabolism and epigenetics

Kenta Masui , Mio Harachi , Webster K. Cavenee , Paul S. Mischel
Cancer Letters 478 1 -7

10
2020
Cholesterol biosynthesis in a variety of cultured cells. lack of correlation between synthesis and activity of 3-hydroxy-3-methylglutaryl coenzyme a reductase caused by dexamethasone

Dean Johnston , Webster K. Cavenee , Chittoor K. Ramachandran , George Melnykovych
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 572 ( 1) 188 -192

28
1979
Effects of various oxygenated sterols on cellular sterol biosynthesis in chinese hamster lung cells resistant to 25-hydroxycholesterol

Webster K. Cavenee , Geoffrey F. Gibbons , Harry W. Chen , Andrew A. Kandutsch
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 575 ( 2) 255 -265

26
1979
Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube

Friedrich Graf Finckenstein , Elai Davicioni , Kent G. Osborn , Webster K. Cavenee
Transgenic Research 15 ( 5) 595 -614

14
2006
Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.

Yetirajam Rajesh , Angana Biswas , Utkarsh Kumar , Indranil Banerjee
Proceedings of the National Academy of Sciences of the United States of America 117 ( 22) 12324 -12331

25
2020
Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule

Swadesh K. Das , Devanand Sarkar , Webster K. Cavenee , Luni Emdad
ACS Chemical Neuroscience 10 ( 3) 1121 -1123

9
2019
Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance

Kazuhiro Tanaka , Ivan Babic , David Nathanson , David Akhavan
Cancer Discovery 1 ( 6) 524 -538

199
2011
De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

David Akhavan , Alexandra L. Pourzia , Alex A. Nourian , Kevin J. Williams
Cancer Discovery 3 ( 5) 534 -547

92
2013
The genetic basis of neoplasia: the retinoblastoma paradigm

Webster K. Cavenee
Trends in Genetics 2 299 -300

15
1986
Retinoblastoma and the progression of tumor genetics

Marc F. Hansen , Webster K. Cavenee
Trends in Genetics 4 ( 5) 125 -128

73
1988
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Ingo K Mellinghoff , Maria Y Wang , Igor Vivanco , Daphne A Haas-Kogan
The New England Journal of Medicine 353 ( 19) 2012 -2024

1,680
2005
Genetics of the malignant progression of astrocytoma

Tom Mikkelsen , J. Gregory Cairncross , Webster K. Cavenee
Journal of Cellular Biochemistry 46 ( 1) 3 -8

31
1991
25
2019
Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics

Jing Cai , Yuan Lin , Haipeng Zhang , Jiankai Liang
Proceedings of the National Academy of Sciences of the United States of America 114 ( 26) 6812 -6817

14
2017
mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

Kenta Masui , Webster K. Cavenee , Paul S. Mischel
Brain Pathology 25 ( 6) 755 -759

19
2015
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

Wei Wei , Young Shik Shin , Min Xue , Tomoo Matsutani
Cancer Cell 29 ( 4) 563 -573

96
2016
MicroRNA-138 Modulates DNA Damage Response by Repressing Histone H2AX Expression

Yemin Wang , Jen-Wei Huang , Ming Li , Webster K. Cavenee
Molecular Cancer Research 9 ( 8) 1100 -1111

127
2011
The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.

Manuela Klingler-Hoffmann , Michelle T. Fodero-Tavoletti , Kazuhiko Mishima , Yoshitaka Narita
Journal of Biological Chemistry 276 ( 49) 46313 -46318

66
2001
Recessive mutant genes predisposing to human cancer

Webster K. Cavenee , Alex Koufos , Marc F. Hansen
Mutation Research/Reviews in Genetic Toxicology 168 ( 1) 3 -14

98
1986
Accumulation of genetic defects during astrocytoma progression

Webster K. Cavenee
Cancer 70 ( S4) 1788 -1793

55
1992